相关实验视频

Updated: Jun 18, 2025

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

驱动器突变亚型涉及与差异化免疫表型影响胰腺癌的结果

Siyi Zou¹, Lei Zhang², Cen Jiang³

¹Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin Er Road, Shanghai, 200025, PR China; Research Institute of Pancreatic Diseases, Shanghai Key Laboratory of Translational Research for Pancreatic Neoplasms, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China; State Key Laboratory of Oncogenes and Related Genes, Institute of Translational Medicine, Shanghai Jiao Tong University, Shanghai, PR China.

|August 2, 2024

概括

胰腺癌患者的KRAS G12V和野生型TP53突变显示出更好的生存率. 这种基因组概况与炎症瘤微环境有关,这表明它是化疗反应的生物标志物.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
基因组学就是基因组学.

背景情况:

胰腺管腺癌 (PAAD) 具有复杂的基因组和免疫格局.
了解驱动突变和免疫特征之间的相互作用对于PAAD预后至关重要.

研究的目的:

研究PAAD中主要驱动突变亚型和免疫类型之间的关系.
识别与不同的免疫微环境和患者结果相关的基因组特征.

主要方法:

分析RNA表达数据以确定PAAD中的免疫亚型.
不同KRAS和TP53突变状态之间的免疫特征的比较.
多重复合免疫组织化学,以表征瘤微环境.

主要成果:

与KRAS G12V / TP53突变患者相比,KRAS G12V / TP53野生型 (wt) 患者表现出炎症性免疫微环境和化学治疗后更高的生存率.
免疫亚型C3 (炎症性,高Th1 / Th2比率) 在KRAS非G12D / TP53体重患者中得到丰富.
免疫亚型C2 (IFN-γ 主导,低Th1/Th2比率) 在KRAS G12D / TP53突变患者中更为普遍.

结论:

在接受辅助化疗的PAAD患者中,KRAS G12V / TP53重量基因型与有利的免疫环境和更好的结果有关.
KRAS G12V / TP53 wt可以作为预测生物标志物,用于识别受益于特定免疫疗法或化疗的PAAD患者.

关键词:

免疫表型类型的免疫表型.在KRAS G12V中使用.新抗原是一种新抗原.胰腺腺癌是什么?胰腺腺腺癌是什么?瘤特异性CD4 (((+) T细胞

更多相关视频

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

相关概念视频

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Forced Transdifferentiation

Forced Transdifferentiation

Transdifferentiation, also known as lineage reprogramming, was first discovered by Selman and Kafatos in 1974 in silkmoths. They observed that the moths’ cuticle-producing cells transformed into salt-producing cells. Many such cases of natural transdifferentiation occur in organisms. In humans, pancreatic alpha cells can become beta cells. In newts, the loss of the eye’s lens causes the pigmented epithelial cells to transdifferentiate into the lens cells.
Artificial...